Intervention Review

Metformin monotherapy for type 2 diabetes mellitus

  1. Antonio Saenz1,*,
  2. Inmaculada Fernandez-Esteban2,
  3. Angel Mataix2,
  4. Monica Ausejo Segura3,
  5. Marta Roqué i Figuls4,
  6. David Moher5

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 20 JUL 2005

Assessed as up-to-date: 30 SEP 2003

DOI: 10.1002/14651858.CD002966.pub3


How to Cite

Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roqué i Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD002966. DOI: 10.1002/14651858.CD002966.pub3.

Author Information

  1. 1

    INSALUD - Madrid, Centro de Salud Pozuelo 1, Pozuelo de Alarcón, Madrid, Spain

  2. 2

    Instituto Madrileño de la Salud, Area 11, Madrid, Madrid, Spain

  3. 3

    Servicio de Farmacia Atencion Frimaria, Madrid, Spain

  4. 4

    CIBER Epidemiología y Salud Pública (CIBERESP), Spain, Iberoamerican Cochrane Centre, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Barcelona, Catalunya, Spain

  5. 5

    Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

*Antonio Saenz, Centro de Salud Pozuelo 1, INSALUD - Madrid, Emisora s/n, Pozuelo de Alarcón, Madrid, 28224, Spain. asaenzcalvo@telefonica.net.

Publication History

  1. Publication Status: Edited (no change to conclusions), comment added to review
  2. Published Online: 20 JUL 2005

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Toshiyuki Nakao, Masaaki Inaba, Masanori Abe, Kazo Kaizu, Kenji Shima, Tetsuya Babazono, Tadashi Tomo, Hideki Hirakata, Tadao Akizawa, Best Practice for Diabetic Patients on Hemodialysis 2012, Therapeutic Apheresis and Dialysis, 2015, 19,
  2. 2
    Márcio Sommer Bittencourt, Ludhmila Abrahao Hajjar, Insulin therapy in insulin resistance: Could it be part of a lethal pathway?, Atherosclerosis, 2015, 240, 2, 400

    CrossRef

  3. 3
    Marcel H A Muskiet, Lennart Tonneijck, Mark M Smits, Mark H H Kramer, Hiddo J Lambers Heerspink, Daniël H van Raalte, Pleiotropic effects of type 2 diabetes management strategies on renal risk factors, The Lancet Diabetes & Endocrinology, 2015, 3, 5, 367

    CrossRef

  4. 4
    Daniel I Bromage, Derek M Yellon, The pleiotropic effects of metformin: time for prospective studies, Cardiovascular Diabetology, 2015, 14, 1

    CrossRef

  5. 5
    Ganna Chornokur, Nagi B. Kumar, Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research, Cancer Causes & Control, 2013, 24, 8, 1465

    CrossRef

  6. 6
    Parag H. Joshi, Rita R. Kalyani, Roger S. Blumenthal, Thomas W. Donner, Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data, The American Journal of Cardiology, 2012, 110, 9, 32B

    CrossRef

  7. 7
    Bincy P. Abraham, Joseph H. Sellin, Drug-induced, factitious, & idiopathic diarrhoea, Best Practice & Research Clinical Gastroenterology, 2012, 26, 5, 633

    CrossRef

  8. 8
    Kathryn Tierney, Therapeutic choices, and the nurse practitioner's role, in type 2 diabetes when metformin alone is no longer enough, Journal of the American Academy of Nurse Practitioners, 2012, 24,
  9. 9
    Carl Asche, Joanne LaFleur, Christopher Conner, A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes, Clinical Therapeutics, 2011, 33, 1, 74

    CrossRef

  10. 10
    Cochrane Clinical Answers, 2011,

    CrossRef

  11. 11
    Cochrane Clinical Answers, 2011,

    CrossRef

  12. You have free access to this content12
    I. W. Campbell, Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?, International Journal of Clinical Practice, 2010, 64, 6
  13. 13
    Heiner C. Bucher, Nutzen und Grenzen von Studien mit Surrogat-Endpunkten in der klinischen Entscheidungsfindung, Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010, 104, 3, 230

    CrossRef

  14. You have free access to this content14
    Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, Stack A, MacIsaac RJ, Girgis S, Colagiuri R, Colagiuri S, Craig J, Prevention and management of chronic kidney disease in type 2 diabetes, Nephrology, 2010, 15,
  15. You have free access to this content15
    Fiona TH Lee, Advances in Diabetes Therapy in the Elderly, Journal of Pharmacy Practice and Research, 2009, 39, 1
  16. 16
    A. Liebl, Insulin intensification – the rationale and the target, International Journal of Clinical Practice, 2009, 63,
  17. 17
    A. Pruna, M. Daudon, Litiasis úrica, EMC - Urología, 2009, 41, 1, 1

    CrossRef

  18. 18
    Shuang Cai, Taoguang Huo, Ning Li, Zhili Xiong, Famei Li, Lysophosphatidylcholine—biomarker of Metformin action: studied using UPLC/MS/MS, Biomedical Chromatography, 2009, 23, 7
  19. 19
    P Joshi, S Joshi, Oral hypoglycaemic drugs and newer agents use in Type 2 diabetes mellitus, South African Family Practice, 2009, 51, 1, 10

    CrossRef

  20. 20
    L. Lundby Christensen, T. Almdal, T. Boesgaard, L. Breum, E. Dunn, B. Gade-Rasmussen, C. Gluud, C. Hedetoft, A. Jarloev, T. Jensen, T. Krarup, L. B. Johansen, S. S. Lund, S. Madsbad, E. Mathiesen, J. Moelvig, F. Nielsen, H. Perrild, O. Pedersen, M. Roeder, S. B. Sneppen, O. Snorgaard, L. Tarnow, B. Thorsteinsson, A. Vaag, H. Vestergaard, J. Wetterslev, N. Wiinberg, Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial, Diabetes, Obesity and Metabolism, 2009, 11, 4
  21. 21
    Maddalena Barba, Holger J. Schünemann, Francesca Sperati, Elie A. Akl, Felice Musicco, Gordon Guyatt, Paola Muti, The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis, Clinical Endocrinology, 2009, 70, 5
  22. 22
    A. Pruna, M. Daudon, Lithiase urique, EMC - Urologie, 2008, 1, 4, 1

    CrossRef

  23. 23
    William F. Miser, The Management of Type 2 Diabetes Mellitus FOCUS on Quality, Primary Care: Clinics in Office Practice, 2007, 34, 1, 1

    CrossRef

  24. 24
    Enrico Carmina, Mild androgen phenotypes, Best Practice & Research Clinical Endocrinology & Metabolism, 2006, 20, 2, 207

    CrossRef

  25. 25
    B Richter, E Bandeira-Echtler, K Bergerhoff, SH Ebrahim, Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus, The Cochrane Library,
  26. 26
    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch, Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus, The Cochrane Library,
  27. 27
    Bincy P Abraham, Joseph H Sellin, Drug-Induced Diarrhea,
  28. 28
    Mohammed A Al-Shareef, Bakr Kalo, Sameer Sabban, Extended-release metformin versus immediate-release metformin for type 2 diabetes mellitus, The Cochrane Library,
  29. 29
    Mohammed A Al-Shareef, Bakr Kalo, Sameer Sabban, Yaser Adi, Extended-release metformin versus immediate-release metformin for type 2 diabetes mellitus, The Cochrane Library,
  30. 30
    Harpreet Kaur, Ruth S. Weinstock, Glycemic treatment of diabetes mellitus,
  31. 31
    Sinead Brophy, Helen Davies, Sopna Mannan, Huw Brunt, Rhys Williams, Interventions for latent autoimmune diabetes (LADA) in adults, The Cochrane Library,
  32. 32
    S Abdelghaffar, AM Attia, Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents, The Cochrane Library,
  33. 33
    Shereen Abdelghaffar, Abdelhamid M Attia, Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents, The Cochrane Library,
  34. 34
    Wei Xin Li, Jian Feng Gou, Xiang Yan, Lin Yang, Metformin for obesity or overweight, The Cochrane Library,
  35. 35
    Wei Xin Li, Jian Feng Gou, Xiang Yan, Lin Yang, Metformin for obesity or overweight, The Cochrane Library,
  36. 36
    Janaina F Andrade, Valter Silva, Tamara Melnik, Mulberry therapy for type 2 diabetes mellitus, The Cochrane Library,
  37. 37
    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christine Clar, Susanne H Ebrahim, Pioglitazone for type 2 diabetes mellitus, The Cochrane Library,
  38. 38
    Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak, Edwin E Salpeter (posthumous), Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, The Cochrane Library,
  39. 39
    Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak, Edwin E Salpeter (posthumous), Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, The Cochrane Library,
  40. 40
    B Richter, E Bandeira-Echtler, K Bergerhoff, C Clar, SH Ebrahim, Rosiglitazone for type 2 diabetes mellitus, The Cochrane Library,
  41. 41
    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christine Clar, Susanne H Ebrahim, Rosiglitazone for type 2 diabetes mellitus, The Cochrane Library,
  42. 42
    Bianca Hemmingsen, Jeppe B Schroll, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, David Peick Sonne, Lars H Lundstrøm, Thomas P Almdal, Sulphonylurea monotherapy for patients with type 2 diabetes mellitus, The Cochrane Library,
  43. 43
    Bianca Hemmingsen, Jeppe B Schroll, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, David Peick Sonne, Lars H Lundstrøm, Thomas P Almdal, Sulphonylurea monotherapy for patients with type 2 diabetes mellitus, The Cochrane Library,
  44. 44
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,
  45. 45
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas P Almdal, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,
  46. 46
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,
  47. 47
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas P Almdal, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,